{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:25:53Z","timestamp":1790717153401,"version":"4.1.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy but are associated with treatment-limiting immune-related cutaneous adverse events (irCAEs). Immune checkpoint inhibitor-related bullous pemphigoid (irBP), a severe, blistering irCAE occurs in 0.3%\u20131.5% of patients receiving ICI therapy. While systemic steroids can be effective, they are associated with significant toxicity and may mitigate \u00adimmunotherapy antitumor efficacy. Consequently, steroid-sparing therapies are needed. Dupilumab, an IL-4 and IL-13 receptor antagonist, has demonstrated efficacy in non-ICI-related BP and appears promising for managing irBP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective review of patients treated with dupilumab for irBP from April 2020 to April 2024. Clinical data, outcomes, and adverse events were assessed. Inhibitor-related bullous pemphigoid response was categorized as complete response (CR), partial response (PR), or no response (NR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In all, 17 patients (59% male, 82% non-Hispanic White; mean age 72.7\u2009years) developed irBP while receiving PD-1\/PDL-1 inhibitors. Sixteen patients (94%) received dupilumab for active irBP and one (6%) for prevention of recurrence. Dupilumab achieved CR of irBP for 12 patients (75%) and PR for 2 (12%) patients with active irBP. Ten (62%) achieved CR with dupilumab systemic monotherapy. Median time to first response was 19.5\u2009days (range\u2009=\u20093\u201350). Most patients with CR (58%) failed prior oral corticosteroid therapy. The patient treated prophylactically experienced no irBP recurrence. Dupilumab was well-tolerated, with no adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Dupilumab is a promising steroid-sparing option for irBP, achieving initial response in under 20\u2009days for most cases. Dupilumab is a valuable tool to manage this challenging irCAE while minimizing risk related to systemic steroid treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf208","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T07:35:02Z","timestamp":1751960102000},"source":"Crossref","is-referenced-by-count":17,"title":["Dupilumab for bullous pemphigoid related to immune checkpoint inhibitors: a retrospective case series"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9620-8276","authenticated-orcid":false,"given":"Ian","family":"Nykaza","sequence":"first","affiliation":[{"name":"Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY 10065,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Moy","sequence":"additional","affiliation":[{"name":"Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY 10065,","place":["United States"]},{"name":"Department of Dermatology, Weill Cornell Medical College , New York, NY 10021,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen W","family":"Dusza","sequence":"additional","affiliation":[{"name":"Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY 10065,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3408-050X","authenticated-orcid":false,"given":"Alison","family":"Moskowitz","sequence":"additional","affiliation":[{"name":"Department of Medicine, Weill Cornell Medical College , New York, NY 10021,","place":["United States"]},{"name":"Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY 10065,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopa","family":"Iyer","sequence":"additional","affiliation":[{"name":"Department of Medicine, Weill Cornell Medical College , New York, NY 10021,","place":["United States"]},{"name":"Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY 10065,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afsheen","family":"Iqbal","sequence":"additional","affiliation":[{"name":"Department of Medicine, Weill Cornell Medical College , New York, NY 10021,","place":["United States"]},{"name":"Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY 10065,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6925-2327","authenticated-orcid":false,"given":"Robert","family":"Motzer","sequence":"additional","affiliation":[{"name":"Department of Medicine, Weill Cornell Medical College , New York, NY 10021,","place":["United States"]},{"name":"Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY 10065,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0831-2247","authenticated-orcid":false,"given":"David H","family":"Ilson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Weill Cornell Medical College , New York, NY 10021,","place":["United States"]},{"name":"Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY 10065,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roisin E","family":"O\u2019Cearbhaill","sequence":"additional","affiliation":[{"name":"Department of Medicine, Weill Cornell Medical College , New York, NY 10021,","place":["United States"]},{"name":"Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY 10065,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashek","family":"Kazi","sequence":"additional","affiliation":[{"name":"Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY 10065,","place":["United States"]},{"name":"Department of Dermatology, Weill Cornell Medical College , New York, NY 10021,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Defazio","sequence":"additional","affiliation":[{"name":"Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY 10065,","place":["United States"]},{"name":"Department of Dermatology, Weill Cornell Medical College , New York, NY 10021,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Gordon","sequence":"additional","affiliation":[{"name":"Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY 10065,","place":["United States"]},{"name":"Department of Dermatology, Weill Cornell Medical College , New York, NY 10021,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2427-3199","authenticated-orcid":false,"given":"Alina","family":"Markova","sequence":"additional","affiliation":[{"name":"Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY 10065,","place":["United States"]},{"name":"Department of Dermatology, Weill Cornell Medical College , New York, NY 10021,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"key":"2025100904570934500_oyaf208-B1","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/1346-8138.16654","article-title":"What\u2019s new in the pathogeneses and triggering factors of bullous pemphigoid","volume":"50","author":"Ujiie","year":"2023","journal-title":"J Dermatol"},{"key":"2025100904570934500_oyaf208-B2","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3390\/biomedicines11020323","article-title":"A review of bullous dermatologic adverse events associated with anti-cancer therapy","volume":"11","author":"Parisi","year":"2023","journal-title":"Biomedicines"},{"key":"2025100904570934500_oyaf208-B3","doi-asserted-by":"publisher","first-page":"898790","DOI":"10.3389\/fmed.2022.898790","article-title":"High grade dermatologic adverse events associated with immune checkpoint blockade for cancer","volume":"9","author":"Kuo","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2025100904570934500_oyaf208-B4","doi-asserted-by":"publisher","first-page":"1416473","DOI":"10.3389\/fimmu.2024.1416473","article-title":"The possible and intriguing relationship between bullous pemphigoid and melanoma: speculations on significance and clinical relevance","volume":"15","author":"Russo","year":"2024","journal-title":"Front Immunol"},{"key":"2025100904570934500_oyaf208-B5","doi-asserted-by":"publisher","DOI":"10.5070\/D327955136","article-title":"Dupilumab for the treatment of nivolumab-induced bullous pemphigoid: a case report and review of the literature","volume":"27","author":"Klepper","year":"2021","journal-title":"Dermatol Online J"},{"key":"2025100904570934500_oyaf208-B6","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/bjd\/ljad149","article-title":"Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment","volume":"189","author":"Shipman","year":"2023","journal-title":"Br J Dermatol"},{"key":"2025100904570934500_oyaf208-B7","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.3390\/jcm11123367","article-title":"Use of dupilumab in bullous pemphigoid: where are We now?","volume":"11","author":"Russo","year":"2022","journal-title":"J Clin Med"},{"key":"2025100904570934500_oyaf208-B8","doi-asserted-by":"publisher","first-page":"1194088","DOI":"10.3389\/fimmu.2023.1194088","article-title":"Dupilumab effectively and rapidly treats bullous pemphigoid by inhibiting the activities of multiple cell types","volume":"14","author":"Yan","year":"2023","journal-title":"Front Immunol"},{"key":"2025100904570934500_oyaf208-B9","doi-asserted-by":"publisher","first-page":"e15623","DOI":"10.1111\/dth.15623","article-title":"Dupilumab for the treatment of pembrolizumab-induced bullous pemphigoid: a case report","volume":"35","author":"Pop","year":"2022","journal-title":"Dermatol Ther"},{"key":"2025100904570934500_oyaf208-B10","doi-asserted-by":"publisher","first-page":"100150","DOI":"10.1016\/j.ejcskn.2024.100150","article-title":"Dupilumab for the treatment of bullous pemphigoid triggered by melanoma immunotherapy","volume":"2","author":"Tsentemeidou","year":"2024","journal-title":"EJC Skin Cancer"},{"key":"2025100904570934500_oyaf208-B11","doi-asserted-by":"publisher","first-page":"e007324","DOI":"10.1136\/jitc-2023-007324","article-title":"Management of immune-related cutaneous adverse events with dupilumab","volume":"11","author":"Kuo","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2025100904570934500_oyaf208-B12","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1001\/jamadermatol.2022.1624","article-title":"Association of bullous pemphigoid with immune checkpoint inhibitor therapy in patients with cancer: a systematic review","volume":"158","author":"Asdourian","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2025100904570934500_oyaf208-B13","doi-asserted-by":"publisher","first-page":"588582","DOI":"10.3389\/fimmu.2020.588582","article-title":"Retrospective analysis of checkpoint inhibitor therapy-associated cases of bullous pemphigoid from six German dermatology centers","volume":"11","author":"Sadik","year":"2020","journal-title":"Front Immunol"},{"key":"2025100904570934500_oyaf208-B14","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.jaad.2023.03.036","article-title":"Long-term treatment outcomes and safety of dupilumab as a therapy for bullous pemphigoid: a multicenter retrospective review","volume":"89","author":"Learned","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2025100904570934500_oyaf208-B15","doi-asserted-by":"publisher","first-page":"1171779","DOI":"10.1155\/2024\/1171779","article-title":"A systematic evaluation of dupilumab for bullous pemphigoid treatment","volume":"2024","author":"Ye","year":"2024","journal-title":"Dermatol Ther"},{"key":"2025100904570934500_oyaf208-B16","doi-asserted-by":"publisher","first-page":"4844","DOI":"10.3390\/jcm13164844","article-title":"Omalizumab and dupilumab for the treatment of bullous pemphigoid: a systematic review","volume":"13","author":"Granados-Betancort","year":"2024","journal-title":"J Clin Med"},{"key":"2025100904570934500_oyaf208-B17","doi-asserted-by":"publisher","first-page":"5451","DOI":"10.3390\/cancers14215451","article-title":"A retrospective, single-institution experience of bullous pemphigoid as an adverse effect of immune checkpoint inhibitors","volume":"14","author":"Shalata","year":"2022","journal-title":"Cancers"},{"key":"2025100904570934500_oyaf208-B18","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.jaad.2020.05.045","article-title":"Management of immune checkpoint inhibitor\u2013induced bullous pemphigoid","volume":"84","author":"Apalla","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2025100904570934500_oyaf208-B19","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1080\/08820139.2020.1832113","article-title":"Association between TH2 cytokine gene polymorphisms and risk of bullous pemphigoid","volume":"51","author":"Tabatabaei-Panah","year":"2022","journal-title":"Immunol Invest"},{"key":"2025100904570934500_oyaf208-B20","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/bjd\/ljad324","article-title":"Targeting interleukin (IL)-4\/IL-13 in immune checkpoint inhibitor-induced bullous pemphigoid: a cautionary note on the beneficial effect of T helper 2 immunity in melanoma and immunotherapy","volume":"190","author":"Guerrero-Juarez","year":"2023","journal-title":"Br J Dermatol"},{"key":"2025100904570934500_oyaf208-B21","doi-asserted-by":"publisher","first-page":"1095694","DOI":"10.3389\/fonc.2023.1095694","article-title":"Analysis of the clinical characteristics of pembrolizumab-induced bullous pemphigoid","volume":"13","author":"Wang","year":"2023","journal-title":"Front Oncol"},{"key":"2025100904570934500_oyaf208-B22","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.3390\/cancers17111845","article-title":"Interleukin-4 and -13 gene expression profiles in immune-related bullous pemphigoid indicate efficacy of IL-4\/IL-13 inhibitors","volume":"17","author":"Arnold","year":"2025","journal-title":"Cancers"},{"key":"2025100904570934500_oyaf208-B23","doi-asserted-by":"publisher","first-page":"e722","DOI":"10.1111\/jdv.19860","article-title":"Checkpoint inhibitor-induced bullous pemphigoid differs from spontaneous bullous pemphigoid","volume":"38","author":"Kramer","year":"2024","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"2025100904570934500_oyaf208-B24","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.3390\/ph16111610","article-title":"Safety of immunomodulatory systemic therapies used in the management of immune-related cutaneous adverse events","volume":"16","author":"Gu","year":"2023","journal-title":"Pharmaceuticals"},{"key":"2025100904570934500_oyaf208-B25","doi-asserted-by":"publisher","first-page":"1068978","DOI":"10.3389\/fimmu.2022.1068978","article-title":"A case report of steroid-refractory bullous pemphigoid induced by immune checkpoint inhibitor therapy","volume":"13","author":"Guan","year":"2022","journal-title":"Front Immunol"},{"key":"2025100904570934500_oyaf208-B26","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s00262-024-03772-9","article-title":"Negative association of steroids with immunotherapy efficacy in a multi-tumor cohort: time and dose-dependent","volume":"73","author":"Albarr\u00e1n","year":"2024","journal-title":"Cancer Immunol Immunother CII"},{"key":"2025100904570934500_oyaf208-B27","doi-asserted-by":"publisher","first-page":"e70254","DOI":"10.1002\/cam4.70254","article-title":"Do corticosteroids affect immunotherapy efficacy in malignancy? \u2013 a systematic review","volume":"13","author":"Byron","year":"2024","journal-title":"Cancer Med"},{"key":"2025100904570934500_oyaf208-B28","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2217\/imt-2020-0265","article-title":"Prognosticating role of serum eosinophils on immunotherapy efficacy in patients with advanced melanoma","volume":"13","author":"Kartolo","year":"2021","journal-title":"Immunotherapy"},{"key":"2025100904570934500_oyaf208-B29","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2217\/imt-2016-0138","article-title":"Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy","volume":"9","author":"Moreira","year":"2017","journal-title":"Immunotherapy"},{"key":"2025100904570934500_oyaf208-B30","doi-asserted-by":"publisher","first-page":"e70010","DOI":"10.1111\/exd.70010","article-title":"Real-world experience of 3-year treatment with dupilumab: significant decrease in circulating neutrophils and eosinophils in Japanese patients with atopic dermatitis","volume":"33","author":"Nakajima","year":"2024","journal-title":"Exp Dermatol"},{"key":"2025100904570934500_oyaf208-B31","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1016\/j.jaip.2022.05.019","article-title":"Effect of dupilumab on blood eosinophil counts in patients with asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, or eosinophilic esophagitis","volume":"10","author":"Wechsler","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025100904570934500_oyaf208-B32","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1111\/cea.13954","article-title":"Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases","volume":"51","author":"Hamilton","year":"2021","journal-title":"Clin Exp Allergy"},{"key":"2025100904570934500_oyaf208-B33","doi-asserted-by":"publisher","first-page":"100317","DOI":"10.1016\/j.jacig.2024.100317","article-title":"Biomarkers and patient-related factors associated with clinical outcomes in dupilumab-treated atopic dermatitis","volume":"3","author":"Kido-Nakahara","year":"2024","journal-title":"J Allergy Clin Immunol Glob"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf208\/63724074\/oyaf208.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/9\/oyaf208\/63724074\/oyaf208.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/9\/oyaf208\/63724074\/oyaf208.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T08:57:15Z","timestamp":1760000235000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf208\/8196220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf208","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,7,10]]},"article-number":"oyaf208"}}